Department of Medicine, Gastroenterology Unit, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Hepatology Division, Department of Hepatobiliary Sciences and Organ Transplant Center, King Abdulaziz Medical City; King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Saudi J Gastroenterol. 2019 May-Jun;25(3):194-200. doi: 10.4103/sjg.SJG_447_18.
BACKGROUND/AIMS: Middle Eastern countries, including Saudi Arabia to some extent, are endemic for chronic hepatitis B (CHB) infection which could be associated with high mortality and comorbidities risk. However, limited data characterizing this CHB population exists. Our aim was to characterize and compare CHB patients in 2015 with those in 2010 and 2012 in Saudi Arabia.
We conducted and compared three cross-sectional analyses of adult patients with CHB defined as either positive hepatitis B surface antigen or documented CHB history in 2010, 2012, and 2015. Data were accessed from the multicenter Systematic Observatory Liver Disease Registry (SOLID).
A total of 765 CHB patients were identified in 2010 (n = 274), 2012 (n = 256), and 2015 (n = 235). Median age was significantly higher in 2015 (47 years) compared to 2010 and 2012 (42 years;P < 0.05). The proportions of patients with hepatocellular carcinoma (range 1-12%) and cirrhosis (range 5-23%) were significantly higher in 2015 compared to 2010 and 2012 (P < 0.05). Compared to 2010, patients in 2015 had significantly (P < 0.05) higher prevalence of coronary artery disease (10% vs. 4%) and hyperbilirubinemia (18% vs. 9%). Although not significant, there was a numerical increase in 2015 in chronic kidney disease (9% vs. 7% in 2010;P= 0.559) and hepatic steatosis (32% vs. 25% in 2010;P= 0.074). Significantly more patients in 2015 (P < 0.05) were treatment experienced (23% vs. 5% in 2010/2012) and switched treatment (17% vs. 1-2% in 2010/2012).
Between 2010 and 2015, the CHB population in Saudi Arabia had significantly aged and was more likely to develop liver disease sequelae and other comorbidities.
背景/目的:包括沙特阿拉伯在内的中东国家普遍存在慢性乙型肝炎(CHB)感染,这可能与高死亡率和合并症风险有关。然而,目前关于这一 CHB 人群的数据有限。我们的目的是描述和比较 2015 年与 2010 年和 2012 年沙特阿拉伯的 CHB 患者。
我们对 2010 年、2012 年和 2015 年分别有阳性乙型肝炎表面抗原或有 CHB 病史的成年 CHB 患者进行了三次横断面分析,并对这些数据进行了比较。数据来自多中心系统肝病观察站(SOLID)。
2010 年(n=274)、2012 年(n=256)和 2015 年(n=235)共发现 765 例 CHB 患者。2015 年患者的中位年龄明显高于 2010 年和 2012 年(47 岁比 42 岁;P<0.05)。2015 年与 2010 年和 2012 年相比,肝癌(1%-12%)和肝硬化(5%-23%)患者的比例明显升高(P<0.05)。与 2010 年相比,2015 年的患者冠心病(10%比 4%)和高胆红素血症(18%比 9%)的患病率显著升高(P<0.05)。尽管没有统计学意义,但 2015 年慢性肾脏病(9%比 2010 年的 7%;P=0.559)和肝脂肪变性(32%比 2010 年的 25%;P=0.074)的发生率略有增加。2015 年接受治疗的患者明显增多(P<0.05)(23%比 2010/2012 年的 5%)和治疗转换(17%比 2010/2012 年的 1-2%)。
2010 年至 2015 年间,沙特阿拉伯的 CHB 人群年龄明显增大,更有可能发展为肝病后遗症和其他合并症。